Publicaciones en colaboración con investigadoras/es de King's College London (62)

2024

  1. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets

    Rheumatology (United Kingdom), Vol. 63, Núm. SI, pp. SI96-SI106

  2. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

    Laboratory investigation; a journal of technical methods and pathology, Vol. 103, Núm. 6, pp. 100147

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 984-995

  5. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study

    Hepatology, Vol. 77, Núm. 2, pp. 512-529

  6. Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas

    Clinical Epigenetics, Vol. 15, Núm. 1

2022

  1. Diagnostic accuracy of the FRAIL scale plus functional measures for frailty screening: a cross-sectional study

    BJGP Open, Vol. 6, Núm. 3

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  3. What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?

    Expert Review of Clinical Immunology

2021

  1. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

    Journal of Clinical Investigation, Vol. 131, Núm. 23

  2. Clinical presentation of antiphospholipid syndrome

    Lahita’s Systemic Lupus Erythematosus (Elsevier), pp. 561-574

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Arthritis and Rheumatology, Vol. 72, Núm. 1, pp. 67-77

  2. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

    Arthritis and Rheumatology, Vol. 72, Núm. 4, pp. 658-666

2018

  1. A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome

    Neurogastroenterology and Motility, Vol. 30, Núm. 9

  2. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients

    Arthritis Care and Research, Vol. 70, Núm. 1, pp. 98-103

2017

  1. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: Results of an international multicentre study

    Lupus, Vol. 26, Núm. 3, pp. 266-276

  2. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210